The Korea Herald CENTER (0.0) Reliability: 7.0/10

Samsung invests in China’s Phrontline Biopharma to bolster ADC capability

✍️ Kan Hyeong-Woo 📅 November 25, 2025 04:25 AM ⏱️ 1 min read 🕐 Scraped: November 26, 2025

Summary: Samsung said Tuesday it had decided to invest in Phrontline Biopharma, a Chinese biotechnology firm with an antibody-drug conjugate platform and pipeline, throu

Samsung said Tuesday it had decided to invest in Phrontline Biopharma, a Chinese biotechnology firm with an antibody-drug conjugate platform and pipeline, through Samsung Life Science Fund.

Samsung Life Science Fund was jointly established by Samsung C&T, Samsung Biologics and S

📰

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Kan Hyeong-Woo

Original Publisher

🌍 The Korea Herald

CENTER Bias (0.0)

Published Date

November 25, 2025 at 04:25 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.